Number of patients
|
98
|
24
| |
102
|
40
| |
Age, years
|
≤ 60
|
69 (70.4)
|
16 (66.7)
|
0.721
|
60 (58.8)
|
19 (47.5)
|
0.222
|
> 60
|
29 (29.6)
|
8 (33.3)
| |
42 (41.2)
|
21 (52.5)
| |
Sex
|
Male
|
65 (66.3)
|
17 (70.8)
|
0.673
|
63 (61.8)
|
26 (65.0)
|
0.720
|
Female
|
33 (33.7)
|
7 (29.2)
| |
39 (38.2)
|
14 (35.0)
| |
Primary tumor location
|
Colon
|
55 (56.1)
|
15 (62.5)
|
0.571
|
71 (69.6)
|
22 (55.0)
|
0.100
|
Rectum
|
43 (43.9)
|
9 (37.5)
| |
31 (30.4)
|
18 (45.0)
| |
Primary tumor differentiation
|
Well to moderate
|
72 (73.5)
|
20 (83.3)
|
0.315
|
83 (81.4)
|
31 (77.5)
|
0.602
|
Poor
|
26 (26.5)
|
4 (16.7)
| |
19 (18.6)
|
9 (22.5)
| |
T stagea
|
1–3
|
50 (53.2)
|
12 (54.5)
|
0.909
|
72 (77.4)
|
23 (67.6)
|
0.261
|
4
|
44 (46.8)
|
10 (45.5)
| |
21 (22.6)
|
11 (32.4)
| |
N stageb
|
0
|
41 (45.6)
|
12 (54.5)
|
0.449
|
37 (40.2)
|
13 (38.2)
|
0.840
|
1–2
|
49 (54.4)
|
10 (45.5)
| |
55 (59.8)
|
21 (61.8)
| |
Timing of metastasis
|
Synchronous
|
74 (75.5)
|
15 (62.5)
|
0.198
|
62 (60.8)
|
20 (50.0)
|
0.242
|
Metachronous
|
24 (24.5)
|
9 (37.5)
| |
40 (39.2)
|
20 (50.0)
| |
Number of metastatic tumors
|
1
|
29 (29.6)
|
9 (37.5)
|
0.453
|
73 (71.6)
|
29 (72.5)
|
0.912
|
2–5
|
69 (70.4)
|
15 (62.5)
| |
29 (28.4)
|
11 (27.5)
| |
Metastases diameter (cm)c
|
≤ 3
|
59 (62.1)
|
14 (58.3)
|
0.735
|
75 (73.5)
|
25 (64.1)
|
0.270
|
> 3
|
36 (37.9)
|
10 (41.7)
| |
27 (26.5)
|
14 (35.9)
| |
Preoperative CEA (ng/mL)d
|
≤ 50
|
78 (82.1)
|
17 (81.0)
|
0.901
|
78 (81.3)
|
27 (69.2)
|
0.128
|
> 50
|
17 (17.9)
|
4 (19.0)
| |
18 (18.8)
|
12 (30.8)
| |
Preoperative CA19-9 (U/mL)e
|
≤ 35
|
70 (76.9)
|
15 (75.0)
|
1.000
|
58 (61.1)
|
23 (62.2)
|
0.906
|
> 35
|
21 (23.1)
|
5 (25.0)
| |
37 (38.9)
|
14 (37.8)
| |
MSKCC-CRSf
|
0–2
|
54 (63.5)
|
9 (47.4)
|
0.193
|
73 (83.0)
|
26 (78.8)
|
0.597
|
3–5
|
31 (36.5)
|
10 (52.6)
| |
15 (17.0)
|
7 (21.2)
| |
Preoperative chemotherapy regimen
|
FOLFOX + XELOX
|
61 (62.2)
|
18 (75.0)
|
0.503
| | | |
FOLFIRI
|
31 (31.6)
|
5 (20.8)
| | | | |
Capecitabine
|
6 (6.1)
|
1 (4.2)
| | | | |
Radiological response to preoperative chemotherapyg
|
PR
|
57 (58.8)
|
13 (54.2)
|
0.683
| | | |
SD
|
30 (30.9)
|
7 (29.2)
| | | | |
PD
|
10 (10.3)
|
4 (16.7)
| | | | |